Welcome to our dedicated page for Amesite SEC filings (Ticker: AMST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Amesite Inc. (NASDAQ: AMST) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. These filings offer detailed information about Amesite’s AI-powered NurseMagic™ platform, its focus on home health and post-acute care markets, and the financial and compliance context surrounding its operations.
Investors can review annual reports on Form 10-K and quarterly reports on Form 10-Q to understand how Amesite describes its business model, revenue sources from B2B and B2C NurseMagic™ subscriptions, risk factors, and internal control disclosures. For example, company materials reference filings that discuss revenue growth associated with NurseMagic™ launches, cost management, and the balance between enterprise and individual users.
Current reports on Form 8-K are particularly relevant for tracking material events. In an 8-K dated October 28, 2025, Amesite reported receiving a Nasdaq deficiency notice related to continued listing standards, outlining timelines and potential remediation steps. Another 8-K filed in June 2025 describes a change in the company’s independent registered public accounting firm and references previously disclosed material weaknesses in internal control over financial reporting.
Users can also monitor proxy statements and executive-related disclosures when available, as well as any Form 4 insider transaction reports that may be filed by Amesite’s officers, directors, or significant shareholders. Stock Titan’s platform enhances these documents with AI-powered summaries designed to clarify complex sections of long filings, highlight key business and risk discussions, and make it easier to locate information on topics such as HIPAA compliance, post-acute care strategy, and Nasdaq listing status.
By reviewing Amesite’s SEC filings with these tools, readers can gain a more structured view of how the company presents its AI healthcare solutions, financial condition, and regulatory environment over time.
Amesite (Nasdaq: AMST) filed an 8-K on June 26 2025 announcing a change in its independent auditor.
The Audit Committee dismissed Turner, Stone & Company, whose FY 2024 report contained a going-concern paragraph, and appointed Novogradac & Company effective June 24 2025.
- No disagreements with the former auditor were reported.
- Previously disclosed material weaknesses in internal controls over journal entries, stock-based compensation and deferred revenue remain a reportable event.
- Turner Stone’s concurrence letter is filed as Exhibit 16.1.
The auditor switch may influence audit timelines, remediation efforts and investor perception of financial reporting quality.